Robert Fishman - 4D Molecular Chief Pulmonology
| FDMT Stock | USD 7.50 0.12 1.57% |
Insider
Robert Fishman is Chief Pulmonology of 4D Molecular Therapeutics
| Age | 62 |
| Address | 5858 Horton Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 505 2680 |
| Web | https://www.4dmoleculartherapeutics.com |
4D Molecular Management Efficiency
The company has return on total asset (ROA) of (0.1686) % which means that it has lost $0.1686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2406) %, meaning that it created substantial loss on money invested by shareholders. 4D Molecular's management efficiency ratios could be used to measure how well 4D Molecular manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.31 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, 4D Molecular's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 800.4 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 14.9 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Diem | Century Therapeutics | 53 | |
| Naomi Cretcher | Biomea Fusion | N/A | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Desiree DDS | Passage Bio | N/A | |
| FACC MD | Stoke Therapeutics | 61 | |
| Marni Kottle | Kronos Bio | N/A | |
| David Pompliano | Revolution Medicines | N/A | |
| Jack Anders | Revolution Medicines | 47 | |
| Thomas Butler | Biomea Fusion | 43 | |
| Gregory Russotti | Century Therapeutics | 57 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Elizabeth Buck | Black Diamond Therapeutics | 49 | |
| Path FRCP | Revolution Medicines | 61 | |
| Kenneth JD | Century Therapeutics | N/A | |
| Richard MD | Gossamer Bio | 63 | |
| Stephan MD | Biomea Fusion | N/A | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| Simona King | Passage Bio | 52 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 |
4D Molecular Therapeutics Leadership Team
Elected by the shareholders, the 4D Molecular's board of directors comprises two types of representatives: 4D Molecular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FDMT. The board's role is to monitor 4D Molecular's management team and ensure that shareholders' interests are well served. 4D Molecular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 4D Molecular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| FAAAAI FAAP, Senior Pulmonology | ||
| Uneek Mehra, Chief Officer | ||
| JD Esq, Chief Officer | ||
| Mike Zanoni, VP Relations | ||
| Fariborz Kamal, President COO | ||
| Noriyuki MD, Chief Officer | ||
| Karen Carothers, Controller | ||
| Fred Kamal, Pres COO | ||
| Raphael MD, VP Cardiology | ||
| MD MBA, VP Ophthalmology | ||
| Theresa Janke, CoFounder Staff | ||
| An Song, Chief Officer | ||
| Robert Fishman, Chief Pulmonology | ||
| David MD, CEO CoFounder | ||
| Dr JD, Chief Secretary | ||
| John Milligan, Executive Chairman |
FDMT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 4D Molecular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (124.8 M) | ||||
| Shares Outstanding | 46.23 M | ||||
| Shares Owned By Insiders | 3.91 % | ||||
| Shares Owned By Institutions | 96.09 % | ||||
| Number Of Shares Shorted | 8.18 M | ||||
| Price To Book | 0.64 X | ||||
| Price To Sales | 20,721 X | ||||
| Revenue | 20.72 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.